Abiopharma

🔍 Lehman David Aaron (Executive)

Company: Pulmonx Corp (LUNG)

Report Date: 2025-09-02

Detailed Transactions and Holdings:

• Sold 929 shares of Common Stock at $1.6 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 272,110.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,541 shares of Common Stock at $1.6 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 268,569.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 2,068 shares of Common Stock at $1.6 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 266,501.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 3,231 shares of Common Stock at $1.6 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 263,270.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2022.
• F2: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023.
• F3: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024.
• F4: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025.